|
Dako announces a collaboration with OSI Pharmaceuticals, Inc. on Companion Diagnostics
(Marketwire Via Acquire Media NewsEdge) GLOSTRUP, DENMARK, January 28 / MARKET WIRE/ --
Dako collaborates with OSI
Pharmaceuticals, Inc. on a drug-companion
diagnostic co-development program.
Dako, a world-leading provider of cancer diagnostic solutions, such
as pharmDx(TM), has entered into a collaboration with OSI
Pharmaceuticals, Inc., a US-based biopharmaceutical company. Under
the terms of agreement, Dako and OSI Pharmaceuticals, Inc. will
collaborate on developing a new cancer diagnostic test as a potential
companion product for a cancer therapy.
The new cancer diagnostic test is intended to identify patients more
likely to benefit from a specific treatment. The collaboration will
draw on Dako's extensive experience within the development of cancer
diagnostic tests and OSI Pharmaceuticals' thorough knowledge in
developing and commercializing novel pharmaceutical products.
"I am happy to announce our collaboration with OSI Pharmaceutical
Inc. The future within Oncology Pharmacotherapy is in targeted
therapies. Linking a drug with a diagnostic test is what you can call
a triple win situation. Most importantly, the patient will receive
relevant therapy from the start instead of a trial-and-error
medication. Secondly, the pharmaceutical company may develop even
more innovative and improved cancer therapies, thereby increasing the
general health within society. Thirdly, Dako itself will continue to
provide Gold Standard companion diagnostics to the market, thereby
contributing to improve the overall health care costs," says Lars
Holmkvist, CEO and President of Dako Denmark A/S.
Dako has a successful history in diagnostic test development, and the
new collaboration is in line with Dako's ongoing strategy to combine
its strengths with pharmaceutical companies to develop the offering
of Dako's pharmDx(TM).
Media contact:
Dako A/S
Sofie Kjaersgaard Hansen
Corporate Communications
+45 6179 0444
Dako, based in Denmark, is a global leader in tissue-based cancer
diagnostics. Hospital and research laboratories worldwide use Dako's
knowledge, reagents, instruments and software to make precise
diagnoses and determine the most effective treatment for patients
suffering from cancer. Employing more than 1000 people and operating
in more than 70 countries, Dako covers essentially all of the global
anatomic pathology markets. Dako is owned by a private equity fund,
EQT. www.dako.com
This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.
Copyright ? Hugin AS 2009. All rights reserved.
Copyright ? 2009 Marketwire
[ Back Small Business VoIP Global Community's Homepage ]
|
SUBSCRIPTIONS
Activate Email 
TMCnet LOGIN
